Sermorelin Regulatory Status: US, EU, Canada, and UK

What Sermorelin Is and How It Works

Sermorelin acetate is the synthetic 29-amino-acid fragment (GRF 1-29 NH₂) of endogenous 44-amino-acid growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on anterior pituitary somatotrophs, triggering pulsatile release of endogenous growth hormone (GH) through a cyclic-AMP-mediated signaling cascade [1]. Unlike exogenous recombinant GH (somatropin), sermorelin preserves the hypothalamic-pituitary feedback loop: GH and IGF-1 elevations still activate somatostatin-mediated negative feedback, which reduces the risk of supraphysiologic GH spikes (Mayo et al., 1995) [2].

The 1-29 fragment retains full receptor-binding potency. Early structure-activity mapping by Ling et al. demonstrated that residues 1-29 are both necessary and sufficient for GHRH receptor activation (Ling et al., 1984) [3]. The acetate salt form improves aqueous solubility for subcutaneous injection. Standard dosing in adult off-label use is 200-300 mcg subcutaneously at bedtime, timed to coincide with the physiologic nocturnal GH pulse (Vittone et al., 1997) [4].

Peak serum GH concentration after a single subcutaneous dose typically occurs at 30-60 minutes. The plasma half-life is approximately 11-12 minutes, similar to native GHRH (Frohman & Jansson, 1986) [5]. This short half-life is one reason daily or even twice-daily dosing protocols have been studied in growth hormone deficiency (GHD) populations.

United States: From FDA Approval to 503A Compounding

Sermorelin's US regulatory arc has three distinct phases. The FDA first approved sermorelin acetate for injection as Geref Diagnostic in 1997 for evaluating pituitary GH secretory capacity (FDA Drugs@FDA record) [6]. EMD Serono also obtained approval for Geref (sermorelin acetate for injection) as a therapeutic product for idiopathic GHD in children with growth failure.

The key pediatric trial was Walker et al. (1990, Pediatrics), a multicenter study showing that sermorelin 30 mcg/kg/day subcutaneously increased growth velocity from a baseline of approximately 3.8 cm/year to 7.0 cm/year over 12 months in children with documented GHD (Walker et al., 1990) [7].

EMD Serono voluntarily withdrew both Geref products from the market in 2008, citing commercial reasons rather than safety or efficacy concerns. The FDA Orange Book lists the NDA as discontinued [8]. Because the withdrawal was not for safety reasons, sermorelin was not placed on the FDA's "withdrawn or removed" list under 21 CFR 216.24.

That distinction matters. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist in a state-licensed compounding pharmacy may compound sermorelin acetate pursuant to a valid patient-specific prescription, provided the drug substance meets USP-NF compendial standards or is manufactured by an FDA-registered facility (FDA guidance on 503A compounding) [9]. The bulk drug substance must not appear on the FDA's "do not compound" list. As of May 2026, sermorelin acetate is not on that list.

Section 503B outsourcing facilities may also produce sermorelin, but they must register with the FDA, comply with current good manufacturing practice (cGMP) requirements, and report adverse events (FDA 503B guidance) [10]. The practical result: most sermorelin prescribed in the US today comes from 503A or 503B compounding pharmacies, not from a branded manufacturer.

Sermorelin is not classified as a controlled substance by the DEA. It does not appear on Schedules I-V. State-level regulations vary: some states restrict compounding of injectable peptides or require additional labeling, so prescribers should verify their state pharmacy board rules.

European Union: No EMA Marketing Authorization

The European Medicines Agency (EMA) has never granted a centralized or mutual-recognition marketing authorization for sermorelin acetate. It does not appear in the Community Register of medicinal products [11]. No company has submitted a Marketing Authorization Application (MAA) through either the centralized or decentralized procedure.

In the EU, unauthorized medicinal products can sometimes be accessed through named-patient or compassionate-use frameworks established by individual member states under Article 5(1) of Directive 2001/83/EC. Germany's "Einzelimport" provision, France's "autorisation temporaire d'utilisation" (ATU, now replaced by the early access framework), and similar pathways in other member states could theoretically permit a physician to obtain compounded sermorelin for a specific patient (EMA regulatory overview) [12]. In practice, this pathway is rarely used for sermorelin because recombinant GH (somatropin) and newer GH secretagogues like macimorelin (approved for diagnostic use) are readily available.

European prescribers evaluating pituitary function are far more likely to use the GHRH-arginine stimulation test with synthetic GHRH (somatorelin, GRF 1-44) or the macimorelin oral test, which received EMA authorization in 2018 (EMA macimorelin EPAR) [13]. The Endocrine Society's 2011 clinical practice guideline on adult GHD diagnosis lists GHRH-arginine and insulin tolerance tests as preferred provocative tests (Molitch et al., 2011) [14].

Canada: Not Listed on the Drug Product Database

Health Canada has not issued a Drug Identification Number (DIN) or Notice of Compliance (NOC) for sermorelin acetate. It does not appear in the Drug Product Database [15]. No Natural Product Number (NPN) applies because sermorelin is a prescription injectable, not a natural health product.

Canadian physicians can access non-marketed drugs through the Special Access Programme (SAP), which permits use of a drug not sold in Canada when conventional therapies have failed or are unsuitable (Health Canada SAP) [16]. SAP requests are reviewed case by case. The treating physician must provide clinical justification and take responsibility for patient monitoring.

Compounding pharmacies in Canada operate under provincial pharmacy regulations rather than a direct federal equivalent of the US 503A framework. In provinces like Ontario, the Ontario College of Pharmacists permits compounding of non-commercially-available formulations under a prescription, but the compounding pharmacy must source an active pharmaceutical ingredient (API) of suitable quality. Because sermorelin acetate has no DIN, the API must typically be imported, which introduces additional regulatory steps under Health Canada's importation rules.

United Kingdom: Specials Manufacturing and Unlicensed Imports

The Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorization (product license) for sermorelin in the UK. It does not hold a PL number. Post-Brexit, the UK operates its own regulatory pathway independent of the EMA.

UK prescribers can access unlicensed medicines through two routes. First, "specials" manufacturers holding a Manufacturer's Specials Licence (MS) can compound sermorelin to order against a valid prescription (MHRA guidance on specials) [17]. Second, an unlicensed medicinal product can be imported by a holder of a Wholesale Dealer's Licence (WDI) for a named patient, provided a licensed alternative does not meet the clinical need.

The General Medical Council (GMC) guidance on prescribing unlicensed medicines states that the prescriber must be satisfied that an alternative licensed medicine would not meet the patient's needs, must take responsibility for the prescription, and must document the rationale (GMC prescribing guidance) [18]. In practice, UK endocrinologists rarely prescribe sermorelin because somatropin products (Genotropin, Norditropin, Humatrope, and others) carry full MHRA marketing authorizations for both pediatric and adult GHD.

Why the Branded Product Disappeared

EMD Serono's 2008 withdrawal of Geref was driven by market dynamics, not a safety signal. By the mid-2000s, recombinant GH products had established a dominant commercial position in the GHD treatment market, with global somatropin sales exceeding $3 billion annually. Sermorelin's market share was negligible. The GH stimulation test indication faced competition from the insulin tolerance test (ITT), which requires no proprietary drug, and later from macimorelin.

No FDA safety alert, boxed warning addition, or adverse event signal preceded the discontinuation. The FDA MedWatch database contains no withdrawal notice based on safety grounds for sermorelin [19]. This distinction keeps the compound eligible for 503A compounding. Had it been withdrawn for safety, it would appear on the 21 CFR 216.24 list, and compounding would be prohibited.

Clinical Evidence Base and Its Limitations

The evidence supporting sermorelin's clinical use is narrower than many patients assume. The Walker et al. (1990) trial remains the highest-quality study: 20 children with GHD treated with sermorelin 30 mcg/kg/day showed growth velocity increases that were clinically meaningful, though the sample was small and the trial was not placebo-controlled in the traditional sense (Walker et al., 1990) [7].

In adults, Vittone et al. (1997) studied sermorelin 2 mg subcutaneously at bedtime in 9 healthy older men for 14 days. Mean 24-hour GH secretion increased, but the study was too small and too short to draw conclusions about body composition or clinical endpoints (Vittone et al., 1997) [4]. Khorram et al. (2001) conducted a 16-week randomized trial of sermorelin (modified depot form, 1 mg/day) in 16 older adults, showing modest IGF-1 increases without significant adverse events (Khorram et al., 2001) [20].

A systematic review of GHRH analogs by Defined Health (2010) noted that no large-scale, long-duration, placebo-controlled trial of sermorelin in adults has been completed. The Endocrine Society does not recommend sermorelin (or any GH secretagogue) for age-related GH decline in its 2006 position statement on GH and aging (Harman & Blackman, 2004) [21]. The 2011 Endocrine Society guideline on adult GHD focuses on somatropin replacement, not secretagogue therapy (Molitch et al., 2011) [14].

Off-label adult use through compounding pharmacies, while legal, operates in an evidence gap. Clinicians prescribing sermorelin for age-related GH decline should inform patients that data supporting this specific use consist primarily of small pilot studies with surrogate endpoints (IGF-1 levels, GH peaks) rather than hard clinical outcomes.

Regulatory Comparison Table

| Jurisdiction | Approved Product? | Compounding/Access Pathway | Controlled Substance? | |---|---|---|---| | United States | No (Geref discontinued 2008) | 503A/503B compounding with Rx | No | | European Union | No (never submitted) | Named-patient import per member state | No | | Canada | No (no DIN issued) | Special Access Programme; provincial compounding | No | | United Kingdom | No (no PL number) | Specials manufacture; unlicensed import | No |

Sermorelin vs. Other GH Secretagogues: Regulatory Context

Sermorelin's regulatory situation contrasts with newer peptides in the GH secretagogue space. Tesamorelin (Egrifta), a GHRH analog with a trans-3-hexenoic acid modification, holds an active FDA approval for HIV-associated lipodystrophy (FDA Egrifta label) [22]. Macimorelin (Macrilen), a ghrelin-receptor agonist, is FDA-approved for diagnostic evaluation of adult GHD (FDA Macrilen approval) [23].

CJC-1295 (with or without DAF modification), ipamorelin, and other synthetic secretagogues remain unapproved investigational compounds in all four jurisdictions. The FDA issued warning letters to compounding pharmacies marketing CJC-1295/ipamorelin combinations with therapeutic claims. In November 2023, the FDA added several peptides to its bulk drug substances "under review" list, though sermorelin was not among those targeted (FDA compounding policy page) [24].

This regulatory distinction gives sermorelin a comparative advantage in terms of legal accessibility: it has a prior-approval history, it is not on the "do not compound" list, and it is not a controlled substance. These three factors make it one of the more straightforward peptides for a licensed prescriber to compound legally in the US.

Practical Prescribing Considerations

Clinicians in the US who prescribe compounded sermorelin should verify three things. The compounding pharmacy holds a valid state license and (if 503B) FDA registration. The sermorelin API comes from an FDA-registered supplier with a Certificate of Analysis documenting identity, potency, sterility, and endotoxin testing. The prescription is patient-specific (503A) or the outsourcing facility meets cGMP requirements (503B).

Patients should be counseled that compounded sermorelin is not FDA-approved for any current indication, that the evidence base in adults is limited, and that insurance coverage is unlikely. Common injection-site reactions (erythema, pain, swelling) occurred in approximately 17% of subjects in the Walker et al. trial (Walker et al., 1990) [7]. Headache and flushing are also reported. Serious adverse events in published literature are rare, but the total safety database is small.

Baseline and follow-up IGF-1 levels are the standard monitoring biomarker. The American Association of Clinical Endocrinologists (AACE) 2019 growth hormone guidelines recommend keeping IGF-1 within the age-adjusted reference range to minimize theoretical risks of sustained GH elevation (Yuen et al., 2019) [25].